A unit of Fosun International (HKG:0656) agreed to purchase 14,940,694 unlisted shares in Shanghai Henlius Biotech (HKG:2696) from HenLink for a little over HK$367.5 million, a Monday filing with the Hong Kong bourse said.
Shanghai Fosun Pharmaceutical Industrial Development will purchase the shares at HK$24.60 apiece.
The buyer had, in two previous transactions this month, acquired a total of 6,093,619 shares in pharmaceutical firm Henlius Biotech.
Following the completion of all three transactions, conglomerate Fosun International will hold 63.43% of Henlius Biotech's total issued share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.